Results 221 to 230 of about 1,875,273 (281)

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

open access: yesMolecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Oxidized Hadean magmas and Archean mobile-lid tectonics revealed by Jack Hills zircon. [PDF]

open access: yesProc Natl Acad Sci U S A
Houchin SK   +6 more
europepmc   +1 more source

Procedural Theatre: EU-HTA Between Ritual and Purpose-Why the Buyer's Audit Has Outgrown the Transaction. [PDF]

open access: yesJ Mark Access Health Policy
Toumi M   +13 more
europepmc   +1 more source

Discovery of Novel Ligands for the Treatment of Cryptococcus neoformans Infection. [PDF]

open access: yesArch Pharm (Weinheim)
Rocha T   +6 more
europepmc   +1 more source

Fragile research systems, brain drain, and predatory publishing in under-resourced countries. [PDF]

open access: yesMicrolife
Jonjić S   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy